CALC

CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing therapies that modulate calcium release-activated calcium channels for the treatment of life-threatening inflammatory diseases. Headquartered in La Jolla, California, CalciMedica focuses on acute pancreatitis, sepsis-associated acute respiratory distress syndrome, and other critical illnesses involving excessive inflammation. The company's lead product candidate is a selective CRAC channel inhibitor designed to reduce pathological calcium signaling in immune cells, thereby decreasing inflammatory responses that can lead to organ failure and death. CalciMedica's approach targets a fundamental cellular mechanism involved in inflammation, potentially offering benefits across multiple disease states characterized by dysregulated immune activation. The company is conducting clinical trials evaluating its therapy in hospitalized patients with acute conditions where current treatment options are limited. CalciMedica has developed formulations suitable for intravenous administration in critical care settings. The company collaborates with academic medical centers and critical care specialists to advance its clinical programs. CalciMedica's scientific founders include researchers who pioneered understanding of calcium channel biology and its role in disease. The company seeks to address high unmet medical needs in acute inflammatory conditions with significant morbidity and mortality.